A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process

Vox Sanguinis

Volumn 92, Issue 1, 2007, Pages 42-55

  Teschner, W ^a   Butterweck, H A ^a   Auer, W ^a   Muchitsch, E M ^a   Weber, A ^a   Liu, S L ^a   Wah, P S ^a   Schwarz, H P ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

Biochemical characterization; Gammagard SD; Intravenous immunoglobulin; Liquid IGIV; Preclinical characterization

Indexed keywords

IMMUNOGLOBULIN G;

ACUTE TOXICITY; AFFINITY CHROMATOGRAPHY; ANAPHYLAXIS; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; BRONCHOSPASM; CONTROLLED STUDY; DEPRESSION; DOG; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; DYSPNEA; FEMALE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; LIQUID; MALE; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; RABBIT; RAT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOGENICITY;

ANIMALS; DECONTAMINATION; DISINFECTION; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MICE; PHARMACEUTICAL PREPARATIONS; RABBITS; RATS; TREATMENT OUTCOME;

EID: 33845647630     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2006.00846.x     Document Type: Article

References (46)

1. Cohn EJ, Strong LE, Hughes WL, Mulford DJ, Ashworth JN, Melin M, Taylor HL: Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68:459-475
2. Polson A, Potgieter GM, Largier JF, Mears GEF, Jourbet FJ: The fractionation of protein mixtures by linear polymers of high molecular weight. Biochim Biophys Acta 1964; 82:463-475
3. Strauss AJL, Kemp PG, Vannier WE, Goodman HC: Purification of human serum gamma-globulin for immunologic studies: gamma-globulin fragmentation after sulphate precipitation and prolonged dialysis. J Immunol 1964; 93:24-34
4. Oncley JL, Melin M, Richert DA, Cameron JW, Gross PM Jr: The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and β1-lipoprotein into subfractions of human plasma. J Am Chem Soc 1949; 71:541-550
5. Kistler P, Nitschmann H: Large scale production of human plasma fractions. Vox Sang 1962; 7:414-424
6. Pollack M: Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 1983; 147:1090-1098
7. Kim KS, Wass CA, Kang JH, Antony BF: Functional activities of various preparations of human intravenous immunoglobulin against type III group B Streptococcus. J Infect Dis 1986; 153:1092-1097
8. van Furth R, Braat AG, Leijh PC, Gardi A: Opsonic and physicochemical characteristics of intravenous immunoglobulin preparation. Vox Sang 1987; 53:70-75
9. Finlayson JS: History of immunoglobulin use; in Alving BM, Finlayson JS (eds): Immune Globulins: Characteristics and Uses of Intravenous Preparations. Washington, US Government Printing Office, 1980:173-177
10. Hoppe HH, Krebs H-J, Mester Th, Hennig W: Production of anti-Rh gamma globulin for preventive immunization. Munch Med Wochenschr 1967; 34:1749-1752
11. Falksveden L-G: Method for fractionating plasma proteins. Patent Sweden, no. 348942, 1970
12. Falksveden L-G and Lundblad G: Ion exchange and polyethylene glycol precipitation of immunoglubulin G; in Curling JM (ed.): Methods of Plasma Protein Fractionation. London, Academic Press, 1980
13. Lebing W, Remigton KM, Schreiner C, Paul H-I: Properties of a new intravenous immunoglobulin (IGIV-C, 10%) produced by virus inactivation with caprylate and column chromatography. Vox Sang 2003; 84:193-201
14. Tanaka K, Sawatani E, Dias GA, Shigueoka EM, Campos TCXB, Nakao HC, Arashiro F: High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography. Braz J Med Biol Res 2000; 33:27-30
15. Reilley B, Van Herp M, Sermand D, Dentico N: SARS and Carlo Urbani. N Engl J Med 2003; 348:1951-1952
16. Horowitz B, Wiebe ME, Lippin A, Stryker MH: Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 1985; 25:516-522
17. Edwards CA, Piet MP, Chin S, Horowitz B: Tri(n-butyl)phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives. Vox Sang 1987; 52:53-59
18. Horowitz B, Lazo A, Großberg H, Page G, Lippin A, Swan G: Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998; 74:203-206
19. Kim IS, Choi YW, Lee SR, Cho HB, Eo HG, Woo HS, Chang CE, Lee S: Improvement of virus safety of a human intravenous immunoglobulin by low pH incubation. J Microbiol Biotechnol 2001; 11:619-627
20. Uemura Y, Uriyu K, Hirao Y, Takechi K, Ishikawa H, Nakajima T, Kagitani Y, Yokoyama K, Funakoshi S, Nishida M, Yabushita S, Furuta K, Hamamoto Y, Tochikura TS, Yamamoto N: Inactivation and elimination of viruses during fractionation of an intravenous immunoglobulin preparation: liquid heat treatment and polyethylene glycol fractionation. Vox Sang 1989; 56:155-161
21. Caillet-Fauquet P, Di Giambattista M, Draps M-L, Sandras F, Branckaert T, de Launoit Y, Laub R: Continuous-flow UVC irradiation: a new effective, protein activity preserving system for inactivating bacteria and viruses, including erythrovirus B19. J Virol Methods 2004; 118:131-139
22. Burnouf-Radosevich M, Appourchaux P, Huart JJ, Burnouf T: Nanofiltration, a new specific virus elimination method applied to high-purity factor IX and factor XI concentrates. Vox Sang 1994; 67:132-138
23. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N, Tomono T: Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86:225-229
24. Burnouf T, Radosevich M: Nanofiltration of plasma-derived biopharmaceutical products. Haemophilia 2003; 9:24-37
25. Henin Y, Marechal V, Barre-Sinoussi F, Chermann JC, Morgenthaler JJ: Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma. Vox Sang 1988; 54:78-83
26. Trejo S, Hotta J, Lebing W, Stenland C, Storms R, Lee DC, Li H, Petteway S, Remington KM: Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. Vox Sang 2003; 84:176-187
27. Parkkinen J, Rahola A, von Bonsdorff L, Tölö H, Törmä E: A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 2006; 90:97-104
28. Tenold RA: Intravenously injectable immune serum globulin. Patent US, 4396608, 1983
29. Hirao Y, Hashimoto M, Kitamura T, Uemura Y: Room temperature storable immunoglobulin preparation for intravenous injection. Patent US, 6485725, 2002
30. Deutsch HF, Gösting IJ, Alberty RA, Williams JW: Biophysical studies of blood plasma proteins. J Biol Chem 1946; 164:109-118
31. Alving BM, Tankersley DL, Manson BL, Rossi F, Aronson DL, Finlayson JS: Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties. J Lab Clin Med 1980; 96:334-346
32. Staudt A, Böhm M, Knebel F, Grosse Y, Bischoff C, Hummel A, Dahm JB, Borges A, Jochmann N, Wernecke KD, Wallukat G, Baumann G, Felix SB: Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106:2448-2453
33. Eibl J, Linnau Y, Schwarz O: Verfahren zur Inaktivierung von Unverträglichkeitsreaktionen verursachender Substanzen. Patent EP 0120835, 1984
34. Wessler S, Reimer SM, Sheps MC: Biologic assay of a thrombosis-inducing activity in human serum. J Appl Physiol 1959; 14:943-946
35. Derelanko MJ, Hollinger MA (eds): CRC Handbook of Toxicology. Boca Raton, FL: CRC Press, 1995
36. Lee ML, Poon W-Y, Kingdon HS: A two-phase linear regression model for biologic half-life data. J Lab Clin Med 1990; 115(6):745-748
37. Kreil TR, Wieser A, Berting A, Spruth M, Medek C, Pölsler G, Gaida T, Hämmerle T, Teschner W, Schwarz H-P, Barrett PN: Removal of small nonenveloped viruses by anti-body-enhanced nanofiltration during manufacture of plasma derivatives. Transfusion 2006; 46:1143-1151
38. Barandun S, Kistler P, Jeunet F, Isliker H: Intravenous administration of human gamma-globulin. Vox Sang 1962; 7:157-174
39. Kroez M, Kanzy E-J, Gronski P, Dickneite G: Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003; 31:277-286
40. Morell A, Skvaril F, Steinberg AG, van Loghem E, Terry WD: Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 1972; 108:195-206
41. Eibl J, Linnau Y, Schwarz O: Method of determining incompatibility- reaction-causing substances in blood products as well as a method of inactivating said incompatibility-reaction-causing substances. Patent US 4886758, 1986
42. Chanutin A, Curnish RR: The precipitation of plasma proteins by short-chain fatty acids. Arch Biochem Biophys 1960; 89:218-220
43. Roberts P: Resistance of vaccinia virus to inactivation by Solvent/Detergent treatment of blood products. Biologicals 2000; 28:29-32
44. Dichtelmüller H, Rudnick D, Kloft M: Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution. Biologicals 2002; 30:135-142
45. Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, PettewaySR Jr: Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates. Biologicals 2002; 30:153-162
46. Bos OJM, Sunyé DGJ, Nieuweboer CEF, van Engelenburg FAC, Schuitemaker H, Over J: Virus validation of pH 4-treated human immunoglobulin products produced by the Cohn fractionation process. Biologicals 1998; 26:267-276